rare cancer
Daiichi Sankyo’s Turalio becomes first FDA-approved therapy for rare tumour
August 5, 2019Sales and Marketing Cancer, Daiichi Sankyo, FDA, Turalio, US, pharma, rare cancer
Daiichi Sankyo has seen its CSF1R inhibitor Turalio (pexidartinib) approved by the FDA in the treatment of symptomatic tenosynovial giant …
First-ever study in the personalised treatment of rare cancers brings promising results
October 18, 2017Research and Development Cancer, Cancer Research UK, personalised medicine, pharma, rare cancer
The first-ever trial to treat patients for rare cancers in a personalised manner based on the characteristics of their individual …
Rare cancers through the looking glass
June 23, 2017Medical Communications, Research and Development pharmafile, rare cancer
Rare cancers are not so rare after all. According to the organisation Rare Cancer Europe more than 4.3 million people …
GSK and Adaptimmune expand R&D collaboration
February 3, 2016Research and Development Adaptimmune, GSK, T-cell therapy, immunotherapy, liposarcoma, rare cancer, sarcoma
Adaptimmune Therapeutics and GlaxoSmithKline have expanded the terms of their strategic collaboration agreement, to run clinical trials of Adaptimmune’s potential …
European Imbruvica approval for Janssen
July 20, 2015Medical Communications, Sales and Marketing B-cell lymphoma, EC, European Commission, Janssen, Waldenström’s Macroglobulinemia, imbruvica, rare cancer
Janssen has received final European sign-off for its oncology treatment Imbruvica (ibrutinib) as a treatment option for adult patients with …
